Marketing Partners Clause Samples

Marketing Partners. If requested by Angioblast, any contracts with Marketing Partners of any Cardiovascular Products for use in the Cardiovascular Field in the Excluded Region engaged by Cephalon other than Cephalon’s Affiliates shall be assigned to Angioblast to the extent Cephalon has the right to do so. In the event such assignment is not requested by Angioblast or Cephalon does not have the right to do so, then the rights of such Marketing Partners shall terminate upon termination of Cephalon’s rights with respect to the Cardiovascular Products for use in the Cardiovascular Field in the Excluded Region. Cephalon shall ensure that its Affiliates and such Marketing Partners (if not assigned to Angioblast pursuant to this Paragraph 8.d) shall transition all Cardiovascular Products for use in the Cardiovascular Field in the Excluded Region back to Angioblast with respect to the Excluded Region in the manner set forth in this Paragraph 8 as if such Affiliate or Marketing Partner were named herein.

Marketing Partners. With ATS' prior written consent (which shall not ------------------ be unreasonably withheld), Buyer shall have the right to appoint one or more third-party marketing partners to promote, co-promote, distribute, market or co-market the ATS Nutrient Solution within the Marketplace in the Territory in accordance with the License granted to Buyer in Section 2.1.

Marketing Partners. Lilly shall have the right to appoint one or more Third Party marketing partners to promote, co-promote, or co-market Drug Product in any territory of the world. In the event Lilly elects to appoint a marketing partner, Lilly shall have the right to supply Drug Product to such partner at such prices as Lilly shall determine. With the consent of Ophidian, which consent will not be unreasonably withheld, Lilly may, in connection with the appointment of a marketing partner, assign to such partner some or all of Lilly's obligations under the Clinical Development Program, provided that such assignment shall not release Lilly from any obligation it may have under this Agreement.

Marketing Partners. Alcon’s Marketing Partners of Licensed Products in such Sub-Field shall, at the request of NovaCal, be assigned to NovaCal to the furthest extent possible. In the event NovaCal does not request assignment of such Marketing Partners, then the rights of such Marketing Partners with respect to Licensed Products in such Sub-Field shall terminate upon termination of Alcon’s rights with respect to such Licensed Products.

Marketing Partners. Provided that the termination of this Agreement is not a termination by Alcon pursuant to Section 12.3, Alcon’s Marketing Partners of Licensed Products shall, at the request of NovaCal, be assigned to NovaCal to the furthest extent possible. In the event NovaCal does not request assignment of such Marketing Partners, then the rights of such Marketing Partners with respect to Licensed Products shall terminate upon termination of Alcon’s rights with respect to Licensed Products.

Marketing Partners. Galderma’s Marketing Partners shall, at the request of NovaBay, be assigned to NovaBay to the extent practicable with respect to Collaboration Products hereunder. In the event NovaBay does not request assignment of such Marketing Partners, then the rights of such Marketing Partners with respect to Collaboration Products shall terminate upon termination of Galderma’s rights with respect to Collaboration Products.

Marketing Partners. Licensee can promote, sponsor or designate third party companies as marketing partners (including but not limited to sponsorship or benefit partnerships) subject to Licensor’s prior approval and Licensee’s compliance with Licensor’s co-marketing guidelines (if applicable), but in any event subject to the terms of this Agreement (including Section 6.6, for the avoidance of doubt); provided that such requirements shall not apply if the Licensed M▇▇▇ is not used by Licensee or any third party in connection with such third-party relationship or partnership.

Marketing Partners. LookSmart shall use best efforts to cause "LookSmart ------------------ Syndicated Sites" and "Third Party Sites" to promote GRC Products in the same manner as such products are promoted by LookSmart on the LookSmart Proprietary Sites from time to time, both in terms of content and premium/fixed positioning. Except as expressly set forth herein, LookSmart shall be solely responsible for all costs associated with the marketing and promotion of the GRC Products, including without limitation all costs and expenses relating to (i) the "storefronts" offered to LookSmart Syndicated Sites and Third Party Sites, (ii) web design, hosting, (iii) software/hardware/ web site maintenance, (iv) upgrades, (v) video streaming" of GRC Infomercials, and (vi) technical support in connection with the marketing and promotion of GRC Products on the LookSmart Syndicated Sites and Third Party Sites, including without limitation the marketing and promotion of ▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. For purposes of this Agreement, "LookSmart Syndicated Sites" shall mean Internet web sites not owned or controlled by LookSmart but which license the right to use LookSmart Content from LookSmart and "Third Party Sites" shall mean Internet web sites other than LookSmart Propietary Web Sites and LookSmart Syndicated Sites.

Marketing Partners. Lilly shall have the right to appoint one or more Third Party marketing partners to promote, co-promote, or co-market Drug Product in any territory of the world. In the event Lilly elects to appoint a marketing partner, Lilly shall have the right to supply Drug Product to such partner at such prices as Lilly shall determine, subject always to its royalty and Bulk Drug Substance purchase obligations to Vertex based on Net Sales of Drug Product by Lilly or its Affiliates, sublicenses or marketing partners. With the consent of Vertex, which consent will not be unreasonably withheld, Lilly may, in connection with the appointment of a marketing partner, assign to such partner some or all of Lilly's obligations under the Clinical Development Program with respect to one or more countries, provided that such assignment shall not release Lilly from any obligations it may have under this Agreement.